Abstract
Several agents have been shown to improve sleep induction and/or maintenance in patients with primary or comorbid insomnia. These include benzodiazepine and non-benzodiazepine receptor allosteric modulators, melatonin and the melatonin receptor agonist ramelteon, low dose doxepin, and suvorexant. However, benzodiazepines induce a further reduction of N3 sleep [slow wave sleep (SWS) or delta sleep] and rapid-eye-movement sleep (REMS), whereas values corresponding to these variables remain decreased during non-benzodiazepine, melatonin, ramelteon or low-dose doxepin administration. By contrast, suvorexant increases REMS. There is evidence indicating that non-selective (ritanserin, ketanserin, sertindole, ICI-170809, ICI-169369, RP-62203, SR-46349B) and selective (volinanserin, pruvanserin, eplivanserin) 5-HT2A receptor antagonists, as well as 5-HT2A receptor inverse agonists (nelotanserin, pimavanserin) increase SWS in laboratory animals and N3 sleep in subjects with normal sleep and/or patients with an insomnia disorder. Thus, the association of a selective 5-HT2A receptor antagonist or a 5-HT2A receptor inverse agonist with a hypnotic drug could be a valid alternative to normalize N3 sleep in patients with an insomnia complaint.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- 5-HT:
-
5-Hydroxytryptamine
- BFB:
-
Basal forebrain
- BZD:
-
Benzodiazepine
- CNS:
-
Central nervous system
- DRN:
-
Dorsal raphe nucleus
- EEG:
-
Electroencephalogram
- EMG:
-
Electromyogram
- EOG:
-
Electro-oculogram
- GABA:
-
γ-Aminobutyric acid
- GAD:
-
Generalized anxiety disorder
- LC:
-
Locus coeruleus
- LDT:
-
Laterodorsal tegmental nucleus
- LS:
-
Light sleep
- MRN:
-
Median raphe nucleus
- NREM:
-
Non-rapid-eye movement
- PPT:
-
Pedunculopontine tegmental nucleus
- REM:
-
Rapid-eye-movement
- SE:
-
Sleep efficiency
- SNc:
-
Substantia nigra pars compacta
- SOL:
-
Sleep onset latency
- SWS:
-
Slow wave sleep
- TST:
-
Total sleep time
- vPAG:
-
Ventral periaqueductal gray matter
- VTA:
-
Ventral tegmental area
- W:
-
Wakefulness
- WASO:
-
Wake time after sleep onset
References
Dement W, Kleitman N (1957) Cyclic variations in EEG during sleep and their relation to eye movements, body motility and dreaming. Electroencephalogr Clin Neurophysiol 9:673–690
Rechtschaffen A, Kales A (1968) A manual of standardized terminology, techniques and scoring system for sleep stages in human subjects. National Institute of Health Publ, Washington, DC. Government Printing Office 204
Adam K, Oswald I (1983) Protein synthesis, bodily renewal and the sleep-wake cycle. Clin Sci (Lond) 65:561–567
Attwell D, Laughlin SB (2001) An energy budget for signaling in the grey matter of the brain. J Cereb Blood Flow Metab 21:1133–1145
Bellesi M, Riedner BA, Garcia-Molina GN et al (2014) Enhancement of sleep slow waves: underlying mechanisms and practical consequences. Front Syst Neurosci 8:208
Whitlock JR, Heynen AJ, Shuler MG (2006) Learning induces long-term potentiation in the hippocampus. Science 313:1093–1097
Xie L, Kang H, Xu Q et al (2013) Sleep drives metabolic clearance from the adult brain. Science 342:373–377
Achermann P, Borbely AA (2003) Mathematical models of sleep regulation. Front Biosci 8:s683–s693
Monti JM, Orellana C, Boussard M et al (1990) 5-HT receptor agonists 1-(2,5-methoxy-4-iodophenyl)-2-aminopro- pane (DOI) and 8-OH-DPAT increase wakefulness in the rat. Biogen Amines 7:145–151
ICSD 2 (2005) International Classification of Sleep Disorders: Diagnostic and Coding Manual, 2nd edn. American Academy of Sleep Medicine, Westchester, IL
Kales A, Kales JD (1984) Evaluation and treatment of insomnia. Oxford University Press, New York
Monti JM (1981) Sleep laboratory and clinical studies of the effects of triazolam, flunitrazepam and flurazepam in insomniac patients. Methods Find Exp Clin Pharmacol 3:303–326
Greenblatt DJ (1991) Benzodiazepine hypnotics: sorting the pharmacokinetic facts. J Clin Psychiatry 52(Suppl):4–10
Monti JM, Pandi-Perumal SR, Langer SZ (2008) Zolpidem: its use in the treatment of sleep disorders. In: Pandi-Perumal SR, Verster JC, Monti JM, Langer SZ (eds) Sleep disorders—diagnosis and therapeutics. Informa Healthcare, London, pp 295–323
Krystal AD, Erman M, Zammit G et al (2008) Long-term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study. Sleep 31:79–90
Monti JM, Spence DW, Pandi-Perumal SR et al (2009) Pharmacotherapy of insomnia. Focus on zolpidem extended release. Clin Med Therap 1:123–140
Dolder CR, Nelson MH (2008) Hypnosedative-induced complex behaviors: incidence, mechanisms and management. CNS Drugs 22:1021–1036
Roehrs TA, Randall S, Harris E et al (2012) Twelve months of nightly zolpidem does not lead to rebound insomnia or withdrawal symptoms: a prospective placebo-controlled study. J Psychopharmacol 26:1088–1095
McCall WV, Erman M, Krystal AD et al (2006) A polysomnographic study of eszopiclone in elderly patients with insomnia. Curr Med Res Opin 22:1633–1642
Scharf M (1999) A new option for insomnia. Health News 5:4
Walsh JK, Vogel GW, Scharf M et al (2000) A five week, polysomnographic assessment of zaleplon 10 mg for the treatment of primary insomnia. Sleep Med 1:41–49
Zammit G, Erman M, Wang-Weigand S et al (2007) Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. J Clin Sleep Med 3:495–504
Krystal AD, Lankford A, Durrence HH (2011) Efficacy and safety of doxepin 3 mg and 6 mg in a 35-day sleep laboratory trial in adults with chronic primary insomnia. Sleep 34:1433–1434
Patel KV, Aspesi AV, Evoy KE (2015) Suvorexant: a dual orexin receptor antagonist for the treatment of sleep onset and sleep maintenance insomnia. Ann Pharmacother 49:477–483
Berridge CW, Schmeichel BE, España RA (2012) Noradrenergic modulation of wakefulness/arousal. Sleep Med Rev 16:187–197
Brown RE, Basheer R, McKenna JT et al (2012) Control of sleep and wakefulness. Physiol Rev 92:1087–1187
Monti JM (2011) Serotonin control of sleep-wake behavior. Sleep Med Rev 15:269–281
Thakkar MM (2011) Histamine in the regulation of wakefulness. Sleep Med Rev 15:65–74
Szymusiak R, Gvilia I, McGinty D (2007) Hypothalamic control of sleep. Sleep Med 8:291–301
Reinoso-Suárez F, de Andrés I, Rodrigo-Angulo ML et al (2001) Brain structures and mechanisms involved in the generation of REM sleep. Sleep Med Rev 5:63–77
Monti JM, Torterolo P, Lagos P (2013) Melanin-concentrating hormone control of sleep-wake behavior. Sleep Med Rev 17:293–298
Hannon J, Hoyer D (2008) Molecular biology of 5-HT receptors. In: Monti JM, Pandi-Perumal SR, Jacobs BL, Nutt DJ (eds) Serotonin and sleep: molecular, functional and clinical aspects. Birkäuser Verlag, Basel, pp 155–182
Cornea-Hébert V, Riad M, Wu C (1999) Cellular and subcellular distribution of the serotonin 5-HT2A receptor in the central nervous system of adult rat. J Comp Neurol 409:187–209
Popa D, Lena C, Favre V et al (2005) Contribution of 5-HT2 receptor subtypes to sleep-wakefulness and respiratory control, and functional adaptations in knock-out mice lacking 5-HT2A receptors. J Neurosci 25:11231–11238
Adrien J (2008) Sleep and waking in mutant mice that do not express various proteins involved in serotonergic neurotransmission such as the serotonergic transporter, monoamine oxidase A, and the 5-HT1A, 5-HT1B, 5-HT2A, 5-HT2C and 5-HT7 receptors. In: Monti JM, Pandi-Perumal SR, Jacobs BL, Nutt DJ (eds) Serotonin and sleep: molecular, functional and clinical aspects. Birkäuser Verlag, Basel, pp 457–475
Done CJ, Sharp T (1994) Biochemical evidence for the regulation of central noradrenergic activity by 5-HT1A and 5-HT2 receptors: microdyalisis studies in the awake and anaesthetized rat. Neuropharmacology 33:411–421
Schmidt CJ, Fadayel GM (1995) The selective 5-HT2A receptor antagonist MDL 100,907, increases dopamine efflux in the prefrontal cortex of the rat. Eur J Pharmacol 273:273–279
Quesseveur G, Repérant C, David DJ, Gardier AM, Sanchez C, Guiard BP (2013) 5-HT2A receptor inactivation potentiates the acute antidepressant-like activity of escitalopram: involvement of the noradrenergic system. Exp Brain Res 226:285–295
Fink KB, Göthert M (2007) 5-HT receptor regulation of neurotransmitter release. Pharmacol Rev 59:360–417
Glennon RA, Titeler M, McKenney JD (1984) Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci 35:2505–2511
Shannon M, Battaglia G, Glennon RA et al (1984) 5-HT1 and 5-HT2 binding properties of derivatives of the hallucinogen 1-(2,5-dimethoxyphenyl)-2-aminopropane (2,5-DMA). Eur J Pharmacol 102:23
Dugovic C, Wauquier A, Leysen JE et al (1989) Functional role of 5-HT2 receptors in the regulation of sleep and wakefulness in the rat. Psychopharmacology 97:436–442
Jäkälä P, Sirviö J, Koivisto E et al (1995) Modulation of rat neocortical high-voltage spindle activity by 5-HT1/5-HT2 receptor subtype specific drugs. Eur J Pharmacol 282:39–55
Monti JM, Jantos H (2006) Effects of the serotonin 5-HT2A/2C receptor agonist DOI and of the selective 5-HT2A or 5-HT2C receptor antagonists EMD 281014 and SB-243213, respectively, on sleep and waking in the rat. Eur J Pharmacol 553:163–170
Boothman LJ, Allers KA, Rasmussen K et al (2003) Evidence that central 5-HT2A and 5-HT2B/C receptors regulate 5-HT cell firing in the dorsal raphe nucleus of the anaesthetised rat. Br J Pharmacol 139:998–1004
Garratt JC, Kidd EJ, Wright IK et al (1984) Inhibition of 5-hydroxytryptamine neuronal activity by the 5-HT agonist. Eur J Pharmacol 199:349–355
Liu R, Jolas T, Aghajanian G (2000) Serotonin 5-HT2 receptors activate local GABA inhibitory inputs to serotonergic neurons of the dorsal raphe nucleus. Brain Res 873:34–45
Boothman LJ, Sharp T (2005) A role for midbrain raphe gamma aminobutyric acid neurons in 5-hydroxytryptamine feedback control. Neuroreport 16:891–896
Ford B, Holmes CJ, Mainville L et al (1995) GABAergic neurons in the rat pontomesencephalic tegmentum: codistribution with cholinergic and other tegmental neurons projecting to the posterior lateral hypothalamus. J Comp Neurol 363:177–196
Vasudeva RK, Waterhouse BD (2014) Cellular profile of the dorsal raphe lateral wing subregion: relationship to the lateral dorsal tegmental nucleus. J Chem Neuroanat 58:15–23
Amici R, Sanford LD, Kearney K et al (2004) A serotonergic (5-HT2) receptor mechanism in the laterodorsal tegmental nucleus participates in regulating the pattern of rapid-eye-movement occurrence in the rat. Brain Res 996:9–18
Rodrigo-Angulo ML, Heredero S, RodrÃguez-Veiga E et al (2008) GABAergic and non-GABAergic, thalamic, hypothalamic and basal forebrain projections to the oral pontine reticular nucleus: their implication in REM sleep regulation. Brain Res 1210:116–125
Vertes RP, Kocsis B (1994) Projections of the dorsal raphe nucleus to the brainstem: PHA-L analysis of the rat. J Comp Neurol 340:11–26
Wang HL, Morales M (2009) Pedunculopontine and laterodorsal tegmental nuclei contain distinct populations of cholinergic, glutamatergic and GABAergic neurons in the rat. Eur J Neurosci 29:340–358
Kirov R, Moyanova S (1998) Age-dependent effect of ketanserin on the sleep-waking phases in rats. Int J Neurosci 93:257–264
Moyanova S, Kortenska L, Kirov R (1998) High-voltage electroencephalogram spindles in rats, aging and 5-HT2 antagonism. Brain Res 786:55–63
Silhol S, Glin L, Gottesmann C (1991) Study of the 5-HT2 antagonist ritanserin on sleep-waking cycle in the rat. Physiol Behav 41:241–243
Kantor S, Jakus R, Bodizs R et al (2002) Acute and long-term effects of the 5-HT2 receptor antagonist ritanserin on EEG power spectra, motor activity and sleep: changes at the light-dark phase shift. Brain Res 943:105–111
Tortella FC, Echevarria E, Pastel RH et al (1989) Suppressant effects of selective 5-HT2 antagonists on rapid eye movement sleep in rats. Brain Res 485:294–300
Stutzmann JM, Eon B, Lucas M (1992) RP 62203, a 5-hydroxytryptamine2 antagonist, enhances deep NREM sleep in rats. Sleep 15:119–124
Coenen AML, Ates N, Skarsfeldt T et al (1995) Effects of sertindole on sleep-wake states, electroencephalogram, behavioral patterns, and epileptic activity of rats. Pharmacol Biochem Behav 51:353–357
Idzikowski C, Mills FJ, Glennard R (1986) 5-Hydroxytryptamine-2-antagonist ritanserin increases human slow wave sleep. Brain Res 378:164–168
Idzikowski C, Cowen PJ, Mills FJ (1987) The effect of chronic ritanserin treatment on sleep and on the neuroendocrine response to L-tryptophan. Psychopharmacology 93:416–420
Idzikowski C, Mills FJ, James RJ (1991) A dose-response study examining the effects of ritanserin on human slow wave sleep. Br J Pharmacol 31:193–196
Kamali F, Stanfield SC, Ashton CH et al (1992) Absence of withdrawal effects of ritanserin following chronic dosing in healthy volunteers. Psychopharmacology 108:213–217
Sharpley AL, Elliott JM, Attenburrow MJ (1994) Slow wave sleep in humans: role of 5-HT2A and 5-HT2C receptors. Neuropharmacology 33:467–471
Sharpley AL, Solomon RA, Fernando AI (1990) Dose-related effects of selective 5-HT2 receptor antagonists on slow wave sleep in humans. Psychopharmacology 101:568–569
Landolt HP, Viola M, Burgess HJ et al (1999) Serotonin-2 receptors and human sleep: effect of a selective antagonist on EEG power spectra. Neuropsychopharmacology 21:455–466
Adam K, Oswald I (1989) Effects of repeated ritanserin on middle-aged poor sleepers. Psychopharmacology 99:219–221
Ruiz-Primo E, Haro R, Valencia M (1989) Polysomnographic effects of ritanserin in insomniacs. A crossed double-blind controlled study. Sleep Res 18:72
Monti JM, Alterwain P, Estévez F et al (1993) The effects of ritanserin on mood and sleep in abstinent alcoholic patients. Sleep 16:647–654
da Roza Davis JM, Sharpley AL, Cowen PJ (1992) Slow wave sleep and 5-HT2 receptor sensitivity in generalized anxiety disorder. Psychopharmacology 108:387–389
Paiva T, Arriaga F, Wauquier A et al (1988) Effects of ritanserin on sleep disturbances of dysthymic patients. Psychopharmacology 96:395–399
Staner L, Kempenaers C, Simonnet MP (1992) 5-HT2 receptor antagonism and slow-wave sleep in major depression. Acta Psychiatr Scand 86:133–137
Kehne JH, Baron BM, Carr AA et al (1996) Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile. J Pharmacol Exp Ther 277:968–981
Bartoszyk GD, van Amsterdam C, Böttcher H (2003) EMD 281014, a new selective serotonin 5-HT2A receptor antagonist. Eur J Pharmacol 473:229–230
Morairty SR, Hedley L, Flores J et al (2008) Selective 5-HT2A and 5-HT6 receptor antagonists promote sleep in rats. Sleep 31:34–44
Hasegawa S, Fikre-Merid M, Diksic M (2012) 5-HT2A receptor antagonist M100907 reduces serotonin synthesis: an autoradiographic study. Brain Res Bull 87:44–49
Monti JM, Jantos H (2011) Effects of the 5-HT6 receptor antagonists SB-399885 and RO-4368554 and of the 5-HT2A receptor antagonist EMD 281014 on sleep and wakefulness in the rat during both phases of the light-dark cycle. Behav Brain Res 216:381–388
Rinaldi-Carmona M, Congy C, Santucci V et al (1992) Biochemical and pharmacological properties of SR 46349B, a new potent and selective 5-hydroxytryptamine2 receptor antagonist. J Pharmacol Exp Ther 262:759–768
Rinaldi-Carmona M, Congy C, Pointeau P et al (1994) Identification of binding sites for SR 463449B, a 5-hydroxytryptamine2 receptor antagonist, in rodent brain. Life Sci 54:119–127
Griebel G, Beeské S, Jacquet A et al (2013) Further evidence for the sleep-promoting effects of 5-HT2A receptor antagonists and demonstration of synergistic effects with the hypnotic zolpidem in rats. Neuropharmacology 70:19–26
Al-Shamma HA, Anderson C, Chuang E et al (2010) Nelotanserin, a novel selective human 5-hydroxytryptamine2A inverse agonist for the treatment of insomnia. J Pharmacol Exp Ther 322:281–290
Teegarden BR, Li H, Jayakumar H, Strah-Pleynet S, Dosa PI, Selaya SD et al (2010) Discovery of 1-[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea (Nelotanserin) and related 5-hydroxytryptamine2A inverse agonists for the treatment of insomnia. J Med Chem 53:1923–1936
Vanover KE, Weiner DM, Makhay M et al (2006) Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N’-4-(2-methylpropylo-xymethyl) carbamide (2R,3R)-dihydroxybu- tanedionate (2,1) (ACP-103), a novel 5-hydroxytryotamine(2A) receptor inverse agonist. L Pharmacol Exp Ther 317:910–918
Rosenberg R, Seiden DJ, Hull SG et al (2008) APD125, a selective serotonin 5-HT2A receptor inverse agonist, significantly improves sleep maintenance in primary insomnia. Sleep 31:1663–1671
Ancoli-Israel S, Vanover KE, Weiner DM et al (2011) Pimavanserin tartrate, a 5-HT2A receptor inverse agonist, increases slow wave sleep as measured by polysomnography in healthy adult volunteers. Sleep Med 12:134–141
Barnes NM, Sharp T (1999) A review of central 5-HT receptors and their functions. Neuropharmacology 38:1083–1152
Leysen JE (2004) 5-HT2 receptors. Curr Drug Targets CNS Neurol Disord 3:11–26
Leysen JE, Gommeren W, Schotte A (1996) Serotonin receptor subtypes: possible roles and implications in antipsychotic drug action. In: Kane JM, Möller H-J, Awouters F (eds) Serotonin and antipsychotic treatment. Marcel Dekker, New York, pp 51–75
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG
About this chapter
Cite this chapter
Monti, J.M., Pandi Perumal, S.R., Warren Spence, D., Torterolo, P. (2018). The Involvement of 5-HT2A Receptor in the Regulation of Sleep and Wakefulness, and the Potential Therapeutic Use of Selective 5-HT2A Receptor Antagonists and Inverse Agonists for the Treatment of an Insomnia Disorder. In: Guiard, B., Di Giovanni, G. (eds) 5-HT2A Receptors in the Central Nervous System. The Receptors, vol 32. Humana Press, Cham. https://doi.org/10.1007/978-3-319-70474-6_13
Download citation
DOI: https://doi.org/10.1007/978-3-319-70474-6_13
Published:
Publisher Name: Humana Press, Cham
Print ISBN: 978-3-319-70472-2
Online ISBN: 978-3-319-70474-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)